In this article, Matt Paterson, Chief Strategy Officer at Quotient Sciences talks about how First-in-human so much more than just safety and the siloed traditional approach to early development leads to expensive delays and lost momentum between teams.
Mat further discusses how an integrated model where real-time manufacturing is harmonized with clinical data, to support adaptive studies, achieve substantial shortening of timelines and leave science (not supply chain, as is currently the case) to dictate the pace.
Continue reading the full article on Clinical Leader.